id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-D-4656-0018,FDA,FDA-2019-D-4656,"Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment
Guidance for Industry; DRAFT GUIDANCE",Other,Guidance,2023-06-06T04:00:00Z,2023,6,2023-06-06T04:00:00Z,2023-08-05T03:59:59Z,2024-11-12T05:49:52Z,,1,0,0900006485abc28f
FDA-2019-D-4656-0017,FDA,FDA-2019-D-4656,"Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment;
Revised Draft Guidance for Industry; Availability",Notice,Notice of Availability,2023-06-05T04:00:00Z,2023,6,2023-06-05T04:00:00Z,,2023-06-05T15:40:29Z,2023-11899,0,0,0900006485abbf3a
FDA-2019-D-4656-0002,FDA,FDA-2019-D-4656,Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): Establishing Effectiveness of Drugs for Treatment Guidance for Industry; Draft Guidance,Other,Guidance,2019-12-05T05:00:00Z,2019,12,2019-12-05T05:00:00Z,,2024-11-12T23:14:07Z,,1,0,09000064841e8091
FDA-2019-D-4656-0001,FDA,FDA-2019-D-4656,Interstitial Cystitis/Bladder Pain Syndrome: Establishing Effectiveness of Drugs for Treatment; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2019-12-05T05:00:00Z,2019,12,2019-12-05T05:00:00Z,2020-02-04T04:59:59Z,2020-02-04T02:03:52Z,2019-26264,0,0,09000064841e7409